(Q44051866)

English

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation

scientific article published in July 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Vincent Delwail

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jean-Philippe Jais

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Pierre Colonna

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jean-Marie Andrieu

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

189-194

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Breast cancer and other second neoplasms after childhood Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Incidence of second cancers in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Acute lymphoblastic leukemia occurring as a second malignancy: report of a case and review of literature

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

How relevant is secondary leukaemia for initial treatment selection in Hodgkin's disease?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Leukemia following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Second acute leukemia and other malignancies following treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03564.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2002.03564.X

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44051866&oldid=2106036660"